Literature DB >> 17516844

Expression of the protein phosphatase 1 inhibitor KEPI is downregulated in breast cancer cell lines and tissues and involved in the regulation of the tumor suppressor EGR1 via the MEK-ERK pathway.

Katrin Wenzel1, Katjana Daskalow, Florian Herse, Susanne Seitz, Ute Zacharias, Jörg A Schenk, Herbert Schulz, Norbert Hubner, Burkhard Micheel, Peter M Schlag, Karl J Osterziel, Cemil Ozcelik, Siegfried Scherneck, Burkhard Jandrig.   

Abstract

KEPI is a protein kinase C-potentiated inhibitory protein for type 1 Ser/Thr protein phosphatases. We found no or reduced expression of KEPI in breast cancer cell lines, breast tumors and metastases in comparison to normal breast cell lines and tissues, respectively. KEPI protein expression and ubiquitous localization was detected with a newly generated antibody. Ectopic KEPI expression in MCF7 breast cancer cells induced differential expression of 95 genes, including the up-regulation of the tumor suppressors EGR1 (early growth response 1) and PTEN (phosphatase and tensin homolog), which is regulated by EGR1. We further show that the up-regulation of EGR1 in MCF7/KEPI cells is mediated by MEK-ERK signaling. The inhibition of this pathway by the MEK inhibitor UO126 led to a strong decrease in EGR1 expression in MCF7/KEPI cells. These results reveal a novel role for KEPI in the regulation of the tumor suppressor gene EGR1 via activation of the MEK-ERK MAPK pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17516844     DOI: 10.1515/BC.2007.062

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  7 in total

Review 1.  Regulation of cellular protein phosphatase-1 (PP1) by phosphorylation of the CPI-17 family, C-kinase-activated PP1 inhibitors.

Authors:  Masumi Eto
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

2.  MK3 controls Polycomb target gene expression via negative feedback on ERK.

Authors:  Hanneke Ec Niessen; Emmanuèle Mouchel-Vielh; Peggy Prickaerts; Vivian Eh Dahlmans; Guus Gh van den Akker; Claudia Geijselaers; Michiel E Adriaens; Frank Spaapen; Yoshihiro Takihara; Ulf R Rapp; Frédérique Peronnet; Jan Willem Voncken
Journal:  Epigenetics Chromatin       Date:  2012-08-07       Impact factor: 4.954

3.  A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer.

Authors:  Changyu Shen; Yiwen Huang; Yunlong Liu; Guohua Wang; Yuming Zhao; Zhiping Wang; Mingxiang Teng; Yadong Wang; David A Flockhart; Todd C Skaar; Pearlly Yan; Kenneth P Nephew; Tim Hm Huang; Lang Li
Journal:  BMC Syst Biol       Date:  2011-05-09

4.  EGR1 upregulation following Venezuelan equine encephalitis virus infection is regulated by ERK and PERK pathways contributing to cell death.

Authors:  Bibha Dahal; Shih-Chao Lin; Brian D Carey; Jonathan L Jacobs; Jonathan D Dinman; Monique L van Hoek; Andre A Adams; Kylene Kehn-Hall
Journal:  Virology       Date:  2019-10-31       Impact factor: 3.616

5.  Statistical and bioinformatic analysis of hemimethylation patterns in non-small cell lung cancer.

Authors:  Shuying Sun; Austin Zane; Carolyn Fulton; Jasmine Philipoom
Journal:  BMC Cancer       Date:  2021-03-12       Impact factor: 4.430

6.  Protein phosphatase 1 regulatory inhibitor subunit 14C promotes triple-negative breast cancer progression via sustaining inactive glycogen synthase kinase 3 beta.

Authors:  Yunting Jian; Lingzhi Kong; Hongyi Xu; Yawei Shi; Xinjian Huang; Wenjing Zhong; Shumei Huang; Yue Li; Dongni Shi; Yunyun Xiao; Muwen Yang; Siqi Li; Xiangfu Chen; Ying Ouyang; Yameng Hu; Xin Chen; Libing Song; Runyi Ye; Weidong Wei
Journal:  Clin Transl Med       Date:  2022-01

7.  Retromer in Osteoblasts Interacts With Protein Phosphatase 1 Regulator Subunit 14C, Terminates Parathyroid Hormone's Signaling, and Promotes Its Catabolic Response.

Authors:  Lei Xiong; Wen-Fang Xia; Fu-Lei Tang; Jin-Xiu Pan; Lin Mei; Wen-Cheng Xiong
Journal:  EBioMedicine       Date:  2016-05-26       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.